Asymptomatic Infections, Drug Resistant Malaria, Migrant Workers
Conditions
Keywords
malaria, falciparum, vivax, Myanmar, migrant workers, asymptomatic infection, drug resistance
Brief summary
A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.
Detailed description
Although malaria prevalence is decreasing in Myanmar, drug resistance threatens the malaria elimination by 2030 especially high risk persons including migrant population. Previous study indicated that asymptomatic malaria parasite carried drug resistance gene such as K13 mutant that is genetically responsible for artemisinin resistant falciparum malaria. These asymptomatic carries may be a source to spread the disease and it is very important to conduct the surveillance on drug resistance status among high vulnerable persons. Unfortunately, there is no study to assess the drug resistance molecular markers in asymptomatic malaria among migrant workers in Myanmar. Therefore, this study fulfills the gaps of knowledge on important of asymptomatic hidden infection exploring to formulate the recommendation for elimination of malaria in Myanmar. In this study, asymptomatic infections are screened by rapid diagnostic test, microscopy and molecular methods.
Interventions
GENETICDrug resistance molecular markers
Proportion of the drug resistance molecular markers will be found-out and compared.
Sponsors
National Malaria Control Program, Myanmar
Department of Medical Research, Lower Myanmar
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age above 6 year * Migrant population (moving from their normal residence place and working at a new place such as forest related activities, gold-mines or plantation sites for more than 3 months- 3 years) * Both sex * Participant who give informed-consent to participate the study
Exclusion criteria
* Known clinical malaria cases regardless of the species detected * Patients with clinical symptoms of malaria at the time of examination * Known history of malaria within 14 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of the asymptomatic infection among the study population | 1 week | Number of the hidden malaria cases by RDT, microscopy or nested PCR (molecular method) |
| Proportion of the drug resistance molecular markers among asymptomatic infections | 3 months | Among the asymptomatic cases, molecular markers will be analyzed (K13 and pfmdr1 copy number for falciparum and pvcrt-o, pvmdr1, pvdhps and pvdhfr gene analysis for vivax cases by Sanger Sequencing. |
Countries
Burma
Outcome results
None listed